
News
from the fight to #SaveIndiePharmacy
New York Times’ The Middlemen series

FTC Releases Second Interim Staff Report on Prescription Drug Middlemen
Report finds PBMs charge significant markups for cancer, HIV, and other critical specialty generic drugs

FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
Caremark, Express Scripts, Optum, and their affiliates created a broken rebate system that inflated insulin drug prices, boosting PBM profits at the expense of vulnerable patients, the FTC alleges.

FTC Releases Interim Staff Report on Prescription Drug Middlemen
Report details how prescription drug middleman profit at the expense of patients by inflating drug costs and squeezing Main Street pharmacies
Drugmakers including Purdue Pharma paid pharmacy benefit managers not to restrict painkiller prescriptions, a New York Times investigation found.